Navigation Links
GenScript Announces Joint Road Show with Open Monoclonal Technology, Inc.

PISCATAWAY, N.J., Jan. 22, 2013 /PRNewswire/ -- GenScript and Open Monoclonal Technology, Inc. (OMT) today announced a joint road show with potential clients across the US, China, Japan and South Korea in late January and early February. The road show will offer prospective clients introductions to GenScript and OMT's human antibody discovery technologies and explore new ways of accelerated and improved development of this important class of human therapeutics.


GenScript offers a full spectrum of human antibody services, including target screening and expression, immunization, monoclonal antibody screening at any desired high complexity, antibody sequencing and characterization, biological and other assays, antibody production cell line development, model animal-based efficacy studies and more. GenScript's antibody development team consists of senior scientists and business managers who have extensive experience in therapeutic antibody development. They have been involved in the full process of therapeutic drug development. GenScript has already successfully gained a top position in gene synthesis worldwide, and has established leading positions in many other biology service areas.

Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for the development of human therapeutic antibodies – naturally optimized human antibodies™. OMT has created OmniRat™, the first fully human monoclonal antibody platform based on transgenic rats. OmniRat™ uses an improved understanding of B cell development and a new approach to inactivation of endogenous antibody expression, which enables them to make antibodies with human idiotypes as efficiently as wild type rats make normal antibodies. OmniRat™ represents a novel and proprietary technology with unrestricted development options for fully human monoclonal antibodies, available worldwide for all targets and indications. OMT also develops a transgenic mouse, OmniMouse™, to complement OmniRat™ and further increase epitope coverage in human antibody development. OmniAb™ integrates OMT's transgenic animal platforms, proven protein- and DNA-mediated immunization and Gel-Encapsulated Microenvironment (GEM) deep antibody screening to enable fast and cost-efficient generation and identification of preferred human therapeutic antibody candidates.

Web site:


SOURCE GenScript USA Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GenScript anuncia un programa conjunto con Open Monoclonal Technology, Inc.
2. GenScript kündigt gemeinsame Roadshow mit Open Monoclonal Technology, Inc. an
3. GenScript anuncia una muestra itinerante conjunta con Open Monoclonal Technology, Inc.
4. GenScript Anuncia Exposição Itinerante Junto com a Open Monoclonal Technology, Inc.
5. TNI BioTech, Inc. Announces Appointment of New CFO
6. NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
7. BioDelivery Sciences Announces Completion of BNX Safety Study
8. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
9. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
10. Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen
11. Ampio Pharmaceuticals Announces Participation at Upcoming Investor Conference
Post Your Comments:
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from reveals that behind the tendency to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):